{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T19:38:30Z","timestamp":1794685110816,"version":"4.9.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The objective of our study was to report real-world data on the safety and efficacy of standard-of-care teclistamab in patients with relapsed\/refractory multiple myeloma (MM). This is a multi-institutional retrospective cohort study and included all consecutive patients that received at least one dose of teclistamab up until August 2023. One hundred and ten patients were included, of whom, 86% had triple-class refractory disease, 76% penta-refractory disease, and 35% had prior exposure to B-cell maturation antigen (BCMA)-targeting therapies. The overall response rate (ORR) in our cohort was 62%, with a \u2265 very good partial remission (VGPR) rate of 51%. The ORR in patients with and without prior BCMA-targeted therapies was 54% vs 67%, respectively (<jats:italic>p<\/jats:italic>\u2009=\u20090.23). At a median follow-up of 3.5\u2009months (range, 0.39\u201310.92), the estimated 3\u2009month and 6\u2009month progression free survival (PFS) was 57% (95% CI, 48%, 68%) and 52% (95% CI, 42%, 64%) respectively. The incidence of cytokine release syndrome (CRS) and immune effector cell associated neurotoxicity syndrome (ICANS) was 56% and 11% respectively, with grade \u22653 CRS and ICANS noted in 3.5% and 4.6% of patients respectively. 78 unique infections were diagnosed in 44 patients, with the incidence of all-grade and grade \u22653 infections being 40% vs 26% respectively. Primary prophylaxis with intravenous immunoglobulin (IVIG) was associated with a significantly lower infection risk on multivariate analysis (Hazard ratio [HR] 0.33; 95% CI 0.17, 0.64<jats:italic>; p<\/jats:italic>\u2009=\u20090.001).<\/jats:p>","DOI":"10.1038\/s41408-024-01003-z","type":"journal-article","created":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T06:02:12Z","timestamp":1709618532000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":115,"title":["Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6913-6526","authenticated-orcid":false,"given":"Meera","family":"Mohan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0854-0768","authenticated-orcid":false,"given":"Jorge","family":"Monge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4723-6745","authenticated-orcid":false,"given":"Nishi","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Luan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Forsberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vineel","family":"Bhatlapenumarthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Metodi","family":"Balev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anannya","family":"Patwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heloise","family":"Cheruvalath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divaya","family":"Bhutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharmilan","family":"Thanendrarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4377-9742","authenticated-orcid":false,"given":"Binod","family":"Dhakal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Zangari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4297-8042","authenticated-orcid":false,"given":"Samer","family":"Al-Hadidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Lentzsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9959-1282","authenticated-orcid":false,"given":"Frits","family":"van Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"D\u2019Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8129-0614","authenticated-orcid":false,"given":"Aniko","family":"Szabo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2699-1741","authenticated-orcid":false,"given":"Carolina","family":"Schinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7336-3003","authenticated-orcid":false,"given":"Rajshekhar","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,5]]},"reference":[{"key":"1003_CR1","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk N, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab in relapsed or refractory multiple Myeloma. N. Engl J Med. 2022;387:495\u2013505.","journal-title":"N. Engl J Med"},{"key":"1003_CR2","doi-asserted-by":"publisher","first-page":"8011","DOI":"10.1200\/JCO.2023.41.16_suppl.8011","volume":"41","author":"NWCJVD Donk","year":"2023","unstructured":"Donk NWCJVD, Moreau P, Garfall AL, Bhutani M, Oriol A, Nooka AK, et al. Long-term follow-up from majesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM). J Clin Oncol. 2023;41:8011.","journal-title":"J Clin Oncol"},{"key":"1003_CR3","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr., Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl J Med. 2021;384:705\u201316.","journal-title":"N. Engl J Med"},{"key":"1003_CR4","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021;398:314\u201324.","journal-title":"Lancet"},{"key":"1003_CR5","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari A, Minnema MC, Berdeja JG, Oriol A, van de Donk N, Rodr\u00edguez-Otero P, et al. Talquetamab, a T-Cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N. Engl J Med. 2022;387:2232\u201344.","journal-title":"N. Engl J Med"},{"key":"1003_CR6","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 magnetisMM-3 trial results. Nat Med. 2023;29:2259\u201367.","journal-title":"Nat Med"},{"key":"1003_CR7","doi-asserted-by":"publisher","first-page":"4416","DOI":"10.1200\/JCO.23.00512","volume":"41","author":"SA Holstein","year":"2023","unstructured":"Holstein SA, Grant SJ, Wildes TM. Chimeric antigen receptor T-Cell and bispecific antibody therapy in multiple myeloma: moving Into the future. J Clin Oncol. 2023;41:4416\u201329.","journal-title":"J Clin Oncol"},{"key":"1003_CR8","doi-asserted-by":"publisher","unstructured":"Hammons L, Szabo A, Janardan A, Bhatlapenumarthi V, Annyapu E, Dhakal B, et al. The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma. Haematologica. 2023. https:\/\/doi.org\/10.3324\/haematol.2023.283590.","DOI":"10.3324\/haematol.2023.283590"},{"key":"1003_CR9","doi-asserted-by":"publisher","first-page":"5898","DOI":"10.1182\/bloodadvances.2023010539","volume":"7","author":"G Reynolds","year":"2023","unstructured":"Reynolds G, Cliff ERS, Mohyuddin GR, Popat R, Midha S, Liet Hing MN, et al. Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis. Blood Adv. 2023;7:5898\u2013903.","journal-title":"Blood Adv"},{"key":"1003_CR10","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","volume":"33","author":"UH Gandhi","year":"2019","unstructured":"Gandhi UH, Cornell RF, Lakshman A, Gahvari ZJ, McGehee E, Jagosky MH, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33:2266\u201375.","journal-title":"Leukemia"},{"key":"1003_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00527-y","volume":"11","author":"R Bansal","year":"2021","unstructured":"Bansal R, Rakshit S, Kumar S. Extramedullary disease in multiple myeloma. Blood Cancer J. 2021;11:161.","journal-title":"Blood Cancer J"},{"key":"1003_CR12","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25:625\u201338.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1003_CR13","doi-asserted-by":"publisher","first-page":"8013","DOI":"10.1200\/JCO.2022.40.16_suppl.8013","volume":"40","author":"C Touzeau","year":"2022","unstructured":"Touzeau C, Krishnan AY, Moreau P, Perrot A, Usmani SZ, Manier S, et al. Efficacy and safety of teclistamab (tec), a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients (pts) with relapsed\/refractory multiple myeloma (RRMM) after exposure to other BCMA-targeted agents. J Clin Oncol. 2022;40:8013.","journal-title":"J Clin Oncol"},{"key":"1003_CR14","doi-asserted-by":"publisher","first-page":"8008","DOI":"10.1200\/JCO.2023.41.16_suppl.8008","volume":"41","author":"AK Nooka","year":"2023","unstructured":"Nooka AK, Lesokhin AM, Mohty M, Niesvizky R, Maisel C, Arnulf B, et al. Efficacy and safety of elranatamab in patients with relapsed\/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: a pooled analysis from magnetisMM studies. J Clin Oncol. 2023;41:8008.","journal-title":"J Clin Oncol"},{"key":"1003_CR15","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1182\/blood-2021-152984","volume":"138","author":"A Lesokhin","year":"2021","unstructured":"Lesokhin A, Iida S, Stevens D, Gabayan AE, Ma WD, Sullivan S, et al. Magnetismm-3: An open-label, multicenter, non-randomized phase 2 study of elranatamab (PF-06863135) in patients with relapsed or refractory multiple myeloma. Blood. 2021;138:1674.","journal-title":"Blood"},{"key":"1003_CR16","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1200\/JCO.22.01365","volume":"41","author":"DK Hansen","year":"2023","unstructured":"Hansen DK, Sidana S, Peres LC, Leitzinger CC, Shune L, Shrewsbury A, et al. Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium. J Clin Oncol.2023;41:2087\u201397.","journal-title":"J Clin Oncol"},{"key":"1003_CR17","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","volume":"6","author":"A Shimabukuro-Vornhagen","year":"2018","unstructured":"Shimabukuro-Vornhagen A, G\u00f6del P, Subklewe M, Stemmler HJ, Schl\u00f6\u00dfer HA, Schlaak M, et al. Cytokine release syndrome. J Immunother Cancer. 2018;6:56.","journal-title":"J Immunother Cancer"},{"key":"1003_CR18","doi-asserted-by":"publisher","first-page":"e2238961","DOI":"10.1001\/jamanetworkopen.2022.38961","volume":"5","author":"LR Hammons","year":"2022","unstructured":"Hammons LR, Szabo A, Janardan A, Dhakal B, Chhabra S, D\u2019Souza A, et al. Kinetics of humoral immunodeficiency with bispecific antibody therapy in relapsed refractory multiple myeloma. JAMA Netw Open. 2022;5:e2238961.","journal-title":"JAMA Netw Open"},{"key":"1003_CR19","doi-asserted-by":"crossref","unstructured":"Lancman G, Parsa K, Kotlarz K, Avery L, Lurie A, Lieberman-Cribbin A, et al. IVIg use associated with ten-fold ueduction of serious infections in multiple myeloma patients treated with Anti-BCMA bispecific atibodies. Blood Cancer Discov. 2023;6:440\u201351.","DOI":"10.1158\/2643-3230.BCD-23-0049"},{"key":"1003_CR20","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1182\/blood.2022015956","volume":"140","author":"N Philipp","year":"2022","unstructured":"Philipp N, Kazerani M, Nicholls A, Vick B, Wulf J, Straub T, et al. T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals. Blood. 2022;140:1104\u201318.","journal-title":"Blood"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01003-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01003-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01003-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T06:02:21Z","timestamp":1709618541000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01003-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,5]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1003"],"URL":"https:\/\/doi.org\/10.1038\/s41408-024-01003-z","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,5]]},"assertion":[{"value":"30 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"35"}}